Trial · NCT03468426
Results by group169
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 169
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1 - Adverse Events (AEs) | Part 1 - BI 836880 360 mg | 3 | Participants | ||
| Part 1 - Adverse Events (AEs) | Part 1 - BI 836880 500 mg | 3 | Participants | ||
| Part 1 - Adverse Events (AEs) | Part 1 - BI 836880 720 mg | 8 | Participants | ||
| Part 1 - Adverse Events (AEs) | Part 1 - total | 14 | Participants | ||
| Part 1 - Drug Related AEs | Part 1 - BI 836880 360 mg | 3 | Participants | ||
| Part 1 - Drug Related AEs | Part 1 - BI 836880 500 mg | 2 | Participants | ||
| Part 1 - Drug Related AEs | Part 1 - BI 836880 720 mg | 7 | Participants | ||
| Part 1 - Drug Related AEs | Part 1 - total | 12 | Participants | ||
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - BI 836880 360 mg | Subjects with AEs leading to dose reduction of trial drug | 0 | Participants | |
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - BI 836880 500 mg | Subjects with AEs leading to dose reduction of trial drug | 0 | Participants | |
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - BI 836880 720 mg | Subjects with AEs leading to dose reduction of trial drug | 0 | Participants | |
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - total | Subjects with AEs leading to dose reduction of trial drug | 0 | Participants | |
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - BI 836880 360 mg | Subjects with AEs leading to discontinuation of trial drug | 1 | Participants | |
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - BI 836880 500 mg | Subjects with AEs leading to discontinuation of trial drug | 1 | Participants | |
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - BI 836880 720 mg | Subjects with AEs leading to discontinuation of trial drug | 2 | Participants | |
| Part 1 - Drug Related AEs Leading to Dose Reduction or Discontinuation | Part 1 - total | Subjects with AEs leading to discontinuation of trial drug | 4 | Participants | |
| Part 2 - Adverse Events (AEs) | Part 2 - Cohort A, 2nd line NSCLC | 39 | Participants | ||
| Part 2 - Adverse Events (AEs) | Part 2 - Cohort B, 3rd line NSCLC | 39 | Participants | ||
| Part 2 - Adverse Events (AEs) | Part 2 - Cohort C, SCLC | 27 | Participants | ||
| Part 2 - Adverse Events (AEs) | Part 2 - Cohort D, glioblastoma | 30 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03468426/results